Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.41 |
| ▸ | IDH2 | P48735 | 4/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1671095 | 0.74 | GABRA1 (0.34) | AAK1 | |
| SCHEMBL16784615 | 0.73 | HSP90AA1 (0.48) | TGFBR1 | |
| SCHEMBL31512367 | 0.72 | MALT1 (0.49) | MALT1TAS2R14 | |
| SCHEMBL16691672 | 0.71 | KDM4E (0.55) | IDH1IDH2 | |
| SCHEMBL30936047 | 0.71 | IDH1 (0.39) | IDH1IDH2TAS2R14IDO1 | |
| SCHEMBL4894244 | 0.71 | IDH1 (0.38) | IDH1IDH2MALT1AAK1TAS2R14 | |
| SCHEMBL19806512 | 0.70 | NOTUM (0.45) | IDH1IDH2 | |
| SCHEMBL1673128 | 0.69 | — | — | |
| SCHEMBL28886728 | 0.69 | AURKA (0.53) | IDH1IDH2MALT1AAK1 | |
| SCHEMBL26128744 | 0.69 | IDO1 (0.33) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594309-A1 | AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024073662-A1 | AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | disclosed |
| EP-1786803-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | Biogen Idec MA, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006026305-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | BIOGEN IDEC MA INC (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | TGFBR1, SMAD3, ALK | IDH1 768/4885IDH2 2029/4885MALT1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.